Drupal.behaviors.print = function(context) {window.print();window.close();}>

Macquarie Begins Coverage on Genomic Health, Myriad Genetics

April 06, 2011

Macquarie Begins Coverage on Genomic Health, Myriad Genetics

Macquarie Capital analyst Dane Leone gave Genomic Health an "Outperform" rating and a $34 price target, and Myriad a "Neutral" rating with a $20 share price.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories